News

Despite the surge in telemental health use in patients with schizophrenia, fewer people in racial or ethnic minority groups had a telemental health visit compared to White people.

The study leverages large US-based claims datasets and pathologist input to estimate the annual incidence and total prevalence of IgAN in the US.

Shadi Kourosh, MD, MPH, joins The Medical Sisterhood to discuss advocacy, mentorship, and the empowerment of women in medicine.

In this episode, hosts explore ADA's evolving guidelines championing broader access to CGM and AID systems for personalized diabetes care.

Boehringer Ingelheim’s phase 3 trial of iclepertin for cognitive impairment in schizophrenia failed to meet primary and secondary endpoints, showing no significant effects.

These data highlight current applications of AI and machine learning in aesthetic medicine, looking specifically at studies graded as Level I or II.

Current asthma diagnosis requires specialized breathing tests that can be challenging for young children.

In a validated microsimulation model, annual CRC screening with FIT was the most cost-effective strategy among patients with low adherence.

UCB announced that a new dosing option for bimekizumab-bkzx is now available through prescription for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

A study shows the causal link between apoA-I and chronic obstructive pulmonary disease, showing lipid metabolism's role in the pathogenesis of COPD.

Based on NHANES data, the age-adjusted prevalence of lean SLD was found to be 12.8%, including a 9.8% prevalence of lean MASLD.

A new study showed ADHD incidence trends fluctuated between 2016-2023, with adult diagnoses rising post-COVID-19 and adolescent rates remaining stable after an initial decline.

With a Phase 3 trial expected in 2025, linsitinib is the first oral small-molecule therapy to demonstrate statistical significance in thyroid eye disease.

The approval is based on data from the phase 3 VIVID-1 study and marks mirikizumab’s second approval in IBD, the first being ulcerative colitis in 2023.

This study pointed to the abilities of patients with acne to adapt to stress and adversity as helpful in making skin-related quality of life improvements.

Anti-CGRP monoclonal antibodies for migraine prevention were not linked to increased cardiovascular risk, per a Medicare study, addressing earlier safety concerns.

A cohort study with 14 years of follow-up found monogenic and polygenic mechanisms influencing LDL-C and incident T2D risk inversely associated.

The analysis of UnitedHealth Group claims data found the per-patient cost of cirrhosis care exceeded that of HF and COPD by 21.7% and 55.0%, respectively.

These retrospective data highlight maternal alopecia areata’s link with the risk of adverse birth outcomes among infants.

The January 15, 2025 SOCS News Update highlights research ongoing/upcoming initiatives and awards, the My Best Winter Skin Campaign, and the TORPEDO program.

2 phase 3 trials show iptacopan improves fatigue, quality of life, and hematologic markers in C5i-experienced or -naive patients with paroxysmal nocturnal hemoglobinuria.

ChatGPT effectively simplified information about more than 60 glomerular disease terms to enhance readability, but medical accuracy decreased.

Within 2 years of death, fall-risk increasing drug burden was associated with greater odds of an injurious fall.

Samsara Vision announced the implantable miniature telescope improved distance and near vision 6 months post-surgery for patients with late-stage AMD.

This analysis is described as the first to identify predictive factors of oral candidiasis in individuals with psoriasis who are treated with bimekizumab.

A study showed age and sex perform better at identifying the risk for opioid use disorder than candidate genetic variants.

Flemming describes increasing rates of AH among adolescents and young adults, with females facing the greatest increases and worse outcomes than males.

An infusion of ferric carboxymaltose in the third trimester significantly reduced anemia in pregnant women, surpassing the efficacy of iron tablets.